Structural Nasal Obstruction

Breathing · §25

A nose that doesn't work properly is one of the most ignored problems in adult medicine and one of the most fixable — once someone actually looks inside. Three structural causes account for almost all chronic nasal blockage: a bent septum (the wall down the middle of your nose), swollen turbinates (the bony shelves on the sides), and nasal polyps (soft inflammatory growths that quietly steal your sense of smell before they block your breathing). The downstream cost is paid in sleep, snoring, daytime energy, and — for polyps — your nose for coffee, gas leaks, and your partner's perfume. The right path through this is a decision tree, not a single move: an ENT evaluation, a real medical trial first, and a clear-eyed look at surgery or one of the new biologic drugs only if medical management runs out.

Decide · As-needed Evidence Moderate Chapter Breathing

The biggest win sits in your sleep — clearing a chronically blocked nose quiets snoring, ends the dry-mouth mornings, and makes CPAP tolerable for people who couldn't stand the mask. For polyp sufferers, smell comes back, and most are surprised how much they'd quietly written off. Expect an ENT visit, several weeks of a medical trial, and a real conversation about whether surgery or one of the newer injectable drugs fits. Cost runs from drugstore-cheap to extraordinary depending on which path you end up on.

Your nose carries roughly half of the resistance air faces from your nostrils down to your lungs, and most of that comes from a narrow slit called the internal nasal valve — the part you can sometimes feel pop open by pulling your cheek sideways. The physics is brutal: resistance scales with the fourth power of how wide the channel is, so a deviation of a single millimetre turns easy breathing into all-day low-grade work Bailey 2018.

A deviated septum is a bent or buckled wall down the middle of your nose, made of cartilage in front and bone behind. Most people have one to some degree — about nine in ten adults on careful exam — but only a minority are bothered by it Mladina et al. 2008. The discriminating sign is laterality: a bent septum steers obstruction toward one nostril and keeps it there.

Turbinate hypertrophy is chronic swelling of the bony shelves on the sides of the nasal cavity. The turbinates are erectile tissue — they swell and shrink on a 4–6 hour cycle as you breathe, alternating which side does most of the work. When allergies, vasomotor inflammation, or weeks of over-the-counter decongestant spray run them down, they stop cycling and stay swollen. The signature is alternating sides and a stuffiness that's worst lying down.

Nasal polyps are soft, pale, grape-like growths from chronic inflammation in the sinus lining. They don't hurt and they grow slowly, which is why the giveaway is usually smell loss long before it's breathing trouble — large polyps sit right under the small patch of nose that detects smell, and air carrying odour molecules stops reaching it Stevens et al. 2016. Polyps cluster strongly with asthma and aspirin sensitivity; the worst-prognosis version is a triad of all three.

The case got stronger in 2019

For septoplasty — straightening the bent septum — the evidence base used to be cohort studies and surgeon experience. Then a pragmatic randomised trial ran the comparison properly and confirmed the surgery actually beats waiting it out.

For nasal polyps the bigger shift is medical, not surgical. Three injected antibody drugs — biologics targeting type-2 inflammation — got approved in quick succession: dupilumab in 2019, omalizumab in 2020, mepolizumab in 2021 Gevaert et al. 2020 Han et al. 2021. In the dupilumab trials, polyps shrank, sinus scans cleared, and smell came back within four weeks. The catch is price — list cost runs into tens of thousands a year — so they're rationed to severe and surgery-refractory cases.

For the everyday case — chronic turbinate swelling from rhinitis, or mild-to-moderate polyps — daily intranasal corticosteroid spray plus saline rinses are the floor. A Cochrane review of 18 trials confirms small but consistent symptom relief that builds over 2–6 weeks Chong et al. 2016. The technique matters as much as the drug; more on that below.

What it costs you to ignore

You stop noticing what you can't breathe. The version of this entry that matters isn't the catastrophic case — it's the partner-noticed snorer who's already accepted dry mornings and a perpetual sniff as normal, and the slowly de-smelling polyp patient who only finds out when a friend points at the fridge.

What's quietly changing is invisible until someone measures it. Population data link chronic nasal obstruction to fragmented sleep, daytime fatigue, and concentration problems — independent of whether you formally have sleep apnoea Sundbom et al. 2021. Untreated nasal polyps drag day-to-day quality of life down to about the same level as severe lung disease on standardised questionnaires — not life-threatening, but life-reducing every single day Hopkins 2019. And chronic nasal obstruction is one of the independent predictors of having undiagnosed obstructive sleep apnoea on population screening Sundh et al. 2020, which on the long timeline is the part that quietly raises your heart-disease risk.

The phone-flip moment for many readers is the smell-loss reveal: noticing they can't detect milk that turned three days ago, or their own kitchen at dinner time, or a gas leak their partner can smell from the doorway. Smell goes slowly enough to grieve unconsciously. Once it's gone for years, getting it back is one of the genuine surprises of treatment.

The decision tree

Step one is a real evaluation by an ear-nose-throat specialist, ideally with a flexible nasal endoscope — a thin camera passed into the nose that takes 30 seconds and shows them what no flashlight-through-the-nostril look ever could. Bring a scored Nasal Obstruction Symptom Evaluation questionnaire (NOSE — five questions, free online, takes a minute), a list of what makes it better or worse, and a record of what you've already tried Stewart et al. 2004.

Almost everyone gets a medical trial first — typically 6–12 weeks of an intranasal corticosteroid spray (mometasone, fluticasone, or budesonide; all over-the-counter in most places) plus high-volume saline rinses (the squeeze-bottle kind, not a quick spritz). About half the cases that walk into clinic get most of what they need from this and never need a scalpel.

If medical management fails after a proper trial, surgery is the next step — and the type depends on which lesion is dominant. Septoplasty straightens the septum (an internal procedure; nothing changes about the outside). Inferior turbinate reduction — submucous resection or radiofrequency — shrinks the swollen shelves while keeping the lining intact. Functional endoscopic sinus surgery removes polyps and opens the sinus drainage paths so topical sprays can reach previously walled-off mucosa.

For severe polyp disease that returns after surgery — especially with asthma or aspirin sensitivity — type-2 biologics are the modern path. Injection every 2–4 weeks, indefinitely, gated through a specialist Orlandi et al. 2021.

Three lines worth holding

A one-sided nasal polyp in an adult is not a polyp until proven otherwise. Unilateral lesions warrant imaging before treatment — inverted papillomas and sinonasal cancers can present this way, and treating them as benign polyps loses time Hopkins 2019.

Don't use over-the-counter decongestant sprays (oxymetazoline, phenylephrine — the Afrin family) for more than 3–5 days. They produce a rebound congestion called rhinitis medicamentosa that locks you into needing them, and it's regularly mistaken for structural obstruction in clinic. The cure is stopping the spray, not adding more.

If turbinate surgery is on the table, ask about mucosa-sparing technique. Aggressive turbinate resection in past decades produced a generation of patients with empty nose syndrome — a paradoxical sense of suffocation in a wide-open cavity, with no reliable treatment Houser 2007. The field has moved to minimally-destructive methods; some surgeons haven't.

What most guides get wrong

"I have a deviated septum" is the most overused self-diagnosis in rhinology. Nearly nine in ten adults have some septal deviation; only a fraction are symptomatic Mladina et al. 2008. If your stuffiness switches sides through the day, swollen-turbinate cycling from rhinitis is more likely the culprit — and the medical trial is what actually moves the needle first.

"Snoring means apnoea, apnoea means fix the nose." Reverse the second half. Isolated nasal surgery rarely cures obstructive sleep apnoea — the main collapse happens lower down, behind the soft palate and tongue base — though it does soften snoring and makes a CPAP mask much easier to live with Georgalas 2011.

"Septoplasty is cosmetic." Septoplasty straightens the internal wall; nothing about the outside of your nose changes. Rhinoplasty is the cosmetic procedure; the two are sometimes done together (septorhinoplasty), but the functional procedure alone is covered by most insurance as medical, not cosmetic.

"Polyps are just bad allergies." They're not. Polyps come from a distinct type of chronic inflammation, and classical allergy is a contributor in some patients but not the cause. The signature is smell loss out of proportion to obstruction, plus the polyps themselves on endoscopy Stevens et al. 2016.

Where this goes wrong in practice

Septoplasty fails about one time in five. The usual reasons are an unrecognised collapse of the soft side-wall of the nostril (internal nasal valve), or hidden turbinate problems that weren't fully addressed in the same surgery van Egmond et al. 2019. A second look — often by a rhinologist rather than a generalist — usually finds something specific rather than "it just didn't work".

Polyps come back. Up to about 60% of severe-phenotype patients have polyp recurrence within five years of surgery Rimmer et al. 2014. The modern model treats polyp disease as a chronic inflammatory condition that sometimes needs surgical episodes — not a one-and-done fix. This is exactly where biologics changed the calculus: ongoing medication instead of repeat trips to theatre.

"I rinsed for a week and nothing happened." Intranasal steroids and saline take 2–6 weeks to plateau, not days. And spray technique matters as much as the medication: head forward, aim outward at the cheek-side wall of the nostril, not straight back into the septum. Most "the spray didn't work" stories are technique stories.

Cost, time, and how this fits into a normal life

In the US, insurance covers septoplasty when there's documented symptom burden (NOSE ≥30 is the usual threshold) plus a 4–8 week failed medical trial. Out-of-pocket without insurance: roughly $5,000–10,000 for septoplasty, more for sinus surgery. Recovery from septoplasty is 1–2 weeks of stuffiness and avoiding nose-blowing; sinus surgery is 2–3 weeks with a couple of follow-up debridement visits in the first month.

Day to day: over-the-counter intranasal corticosteroid sprays (generic mometasone or fluticasone) run under $100 a year. A sinus-rinse kit is under $50/year for once or twice daily use. Biologic injections list at $30,000–40,000 a year with severity criteria for prior authorisation; what you actually pay depends entirely on your insurance.

The workup is one ENT visit (about 30 minutes), maybe a CT scan if polyps or surgery are on the table, then the medical trial timed to your calendar — most of the work is consistency at home, not appointments. Surgery itself is outpatient and rarely needs more than a week of meaningful downtime.

Things people try instead

External nasal dilators — Breathe Right strips, the internal silicone cone things — widen the nostril opening mechanically. They help some snorers and are a useful free diagnostic: if a strip dramatically improves your breathing, you have a soft side-wall problem (internal nasal valve collapse), not a septal one. They don't fix the underlying structure.

Mouth-taping at night forces nasal breathing — but only if your nose is actually patent. If you're chronically structurally obstructed, taping doesn't solve the problem and can make sleep worse. Fix the nose first, then consider whether taping adds anything.

CPAP for sleep apnoea bypasses the upper airway entirely. It treats apnoea but doesn't fix the nose, and nasal obstruction is one of the main reasons people stop using their CPAP. Treating the nose is often what makes the mask survivable.

Allergy management — allergen avoidance, antihistamines, allergen immunotherapy — addresses the rhinitis-driven part of turbinate swelling. It won't move a deviated septum or shrink polyps on its own, but it's almost always part of the picture and worth doing in parallel.

What changes, and when

The payoff timeline depends on which path you end up on.

For medical management — daily steroid spray and saline rinses — the felt change comes in 2–6 weeks. Less constant stuffiness, fewer little sinus infections, mornings without a dry throat. Subtle but durable as long as you stay on the routine. People around you stop describing you as the one with the stuffy voice.

For septoplasty, the first one to two weeks after surgery are worse than baseline — swelling, dried blood, restricted breathing. Then around four to six weeks the post-op swelling clears and the change is striking: the side that was permanently blocked simply isn't anymore. SAMINOSE responders held that gain through 24 months without regression van Egmond et al. 2019.

For polyp treatment — surgery, biologic injection, or both — the headline payoff is smell coming back. In the dupilumab trials, scores on a standardised smell test recovered within four weeks and held across the full year of follow-up Bachert et al. 2019. Patients describe suddenly noticing the kitchen, their partner's shampoo, coffee in a way they hadn't realised they'd stopped detecting. The thing nobody warns you about is how emotional that part is.

The social-mirror version across all three: the snoring complaints stop. People stop asking if you have a cold. Your partner stops elbowing you at 3am. Within months, you forget what it was like to fight for every breath through your nose — which is exactly the way most readers ended up here in the first place.

Adjacent topics worth knowing about: obstructive sleep apnoea (which nasal obstruction feeds but rarely causes alone), upper airway resistance syndrome (the sub-apnoeic version that wakes you tired despite eight hours), chronic sinusitis without polyps (a related but distinct inflammatory disease), allergic rhinitis (the upstream driver of a lot of turbinate swelling), and mouth taping (a tool that only works when the nose underneath is patent). Paediatric airway obstruction — adenoids, tonsils, and their effects on facial development in children — is its own world and isn't covered here.

Related in the handbook

Worsens / aggravates

— Chronic nasal blockage is a frequent cause of the night-time airway narrowing behind UARS.

Helps

— For nasal polyps, an injectable biologic is the newer alternative to surgery when medical management runs out.
— Saline rinsing is part of the medical trial you run before any surgical decision on the nose.

Alternatives

— A dilator is the cheap first thing to try for a stuffy nose before you consider surgery for the structure.

— Allergic swelling and a structural blockage can coexist — treat the inflammation before blaming the anatomy.
— A nose that won't pass air forces mouth breathing at night — fixing the blockage is the upstream cure.
— Fixing the nose is what lets a lot of people finally stick with CPAP for their apnea.
— If nasal breathing feels impossible no matter how you hold your tongue, a structural blockage is the thing to fix first.

1. Substance + claimed effects

Structural nasal obstruction is the umbrella term for fixed anatomical narrowing of the nasal airway, distinct from transient congestion. Three lesions cover almost all cases: deviated nasal septum (a bent or buckled midline cartilage/bone wall), turbinate hypertrophy (chronic enlargement of the inferior turbinates, the bony shelves on the lateral nasal wall), and nasal polyps (eosinophilic inflammatory outgrowths of the sinonasal mucosa, the surface marker of chronic rhinosinusitis with nasal polyps, CRSwNP) Fokkens et al. 2020. The downstream consequences this entry covers, holistically: chronic nasal-airway resistance and the obligate switch toward mouth breathing; degraded sleep quality and a contribution to snoring and obstructive sleep apnoea; loss of olfaction (especially with polyps); reduced exercise tolerance; and the medical–surgical decision tree (intranasal corticosteroids, saline irrigation, type-2 biologics for CRSwNP, septoplasty, turbinate reduction, functional endoscopic sinus surgery) Orlandi et al. 2021.

2. Evidence by addressing question

mechanism

Science. The nose contributes roughly half of total airway resistance from nostril to alveolus, with the dominant bottleneck at the internal nasal valve — the slit-shaped region where the upper and lower lateral cartilages meet the septum, at a normal angle of ~10–15° Bailey 2018. Resistance scales by Poiseuille's law as the inverse fourth power of radius, so a deviation that narrows one side by 1 mm produces a far-larger-than-linear jump in work of breathing. Beyond conducting air, the nose conditions it: turbinate mucosa warms inspired air to ~30–34 °C and raises humidity above 80% before laryngeal entry, while paranasal sinus epithelium continuously produces nitric oxide that diffuses to the lower airway and modulates ventilation–perfusion matching Lundberg 2008.

Septal deviation. Deviations arise from birth-trauma molding, growth asynchrony between the cartilaginous and bony septum, and acquired nasal trauma. They produce unilateral or alternating obstruction; severe deviations narrow the contralateral cavity by mucosal compensation. International endoscopic surveys put septal deformity prevalence at 89% of adults across 2,589 ENT patients in five countries, though only a minority are symptomatic Mladina et al. 2008.

Turbinate hypertrophy. The inferior turbinates are erectile vascular tissue with a venous-sinusoid stroma that swells and shrinks on minutes-to-hours cycles (the normal nasal cycle). Chronic enlargement is driven by allergic and non-allergic rhinitis, vasomotor inflammation, and decongestant rebound (rhinitis medicamentosa from chronic oxymetazoline). Histologically the change is mucosal–submucosal, sometimes with bony enlargement; this distinction matters because soft-tissue hypertrophy responds to topical steroids while bony enlargement needs mechanical reduction Orlandi et al. 2021.

Nasal polyps. Polyps are pale, grape-like sinonasal mucosal outgrowths driven by type-2 inflammation — eosinophils, mast cells, and the IL-4/IL-5/IL-13 cytokine axis dominate, with IgE elevation common Stevens et al. 2016. They arise in the middle meatus and ethmoid sinuses and prolapse into the nasal cavity; large polyps physically block the olfactory cleft (causing smell loss) before they fully obstruct breathing. Strong associations: asthma (40–60% of CRSwNP patients have asthma), aspirin-exacerbated respiratory disease (AERD/Samter's triad, where polyps recur aggressively after aspirin exposure), and allergic fungal sinusitis Settipane and Chafee 1977.

evidence

Septoplasty for symptomatic deviation. The SAMINOSE trial randomized 203 adults with chronic nasal obstruction and septal deviation to septoplasty (with concurrent turbinate surgery as needed) versus non-surgical management van Egmond et al. 2019. At 24 months, the surgical group's Glasgow Health Status Inventory score improved by 11.6 versus 4.7 in controls (between-group difference 8.0 points, p<0.0001), with parallel improvements on the Nasal Obstruction Symptom Evaluation (NOSE) — a 5-item, 0–100 scale that is the field's standard subjective outcome measure Stewart et al. 2004. NOSE drops from baseline averages of 60–80 in obstruction patients to 10–30 after septoplasty in observational cohorts, sustained at 2–5 years.

Intranasal corticosteroids. First-line for both turbinate hypertrophy from rhinitis and CRSwNP. A Cochrane review of 18 trials found intranasal steroids reduce nasal polyp size, improve symptoms, and produce small but consistent quality-of-life gains in CRS (SNOT-22 improvements of 5–10 points are typical) Chong et al. 2016. Effect onset is 2–6 weeks; the magnitude scales with adherence and correct technique (head-forward, cross-handed delivery to the lateral wall).

Surgery for nasal polyps. Functional endoscopic sinus surgery (FESS) removes polyps and opens the sinus drainage pathways, after which topical steroids reach previously inaccessible mucosa. A Cochrane review found surgery plus medical therapy outperforms medical therapy alone on short-term symptom scores, though long-term polyp recurrence is the rule rather than the exception (40–60% recurrence at 5 years in severe phenotypes) Rimmer et al. 2014.

Type-2 biologics for CRSwNP. A genuine therapeutic shift since 2019. Dupilumab (anti-IL-4Rα) in the SINUS-24 and SINUS-52 trials (n=724) reduced nasal polyp score by 1.71–2.05 points (0–8 scale) and Lund–Mackay sinus CT score by 5–6 points versus placebo, restored smell on UPSIT testing within 4 weeks, and roughly halved the need for rescue surgery — gaining FDA approval in 2019 Bachert et al. 2019. Omalizumab (anti-IgE) in POLYP 1 and POLYP 2 showed similar polyp shrinkage and SNOT-22 improvement, approved 2020 Gevaert et al. 2020. Mepolizumab (anti-IL-5) in SYNAPSE (n=407) reduced surgery rates and polyp burden, approved 2021 Han et al. 2021. List prices run $30–40k per year in the US; access in most health systems is gated to severe, surgery-refractory patients.

protocol

The protocol is a decision tree, not a single action. Workup begins with a primary-care or ENT visit documenting symptoms (laterality, persistence, smell change, snoring, prior nasal trauma), a NOSE or SNOT-22 questionnaire Hopkins et al. 2009, anterior rhinoscopy, and ideally nasal endoscopy. CT of the sinuses is reserved for CRSwNP workup or surgical planning Fokkens et al. 2020. Medical first. For every structural cause, 6–12 weeks of high-volume saline irrigation plus an intranasal corticosteroid spray (fluticasone, mometasone, budesonide) is the floor. Short oral corticosteroid courses may be added for polyps. Surgery when medical fails. Septoplasty for symptomatic deviation; submucous resection or radiofrequency ablation for inferior turbinate reduction (preserve mucosa — see below); FESS for polyps. Biologics for refractory CRSwNP with comorbid asthma, AERD, or polyp recurrence after surgery Orlandi et al. 2021.

contraindications

Surgery is electively scheduled; absolute contraindications are uncommon and are the surgical team's call, not the entry's. The catalogue-level call-outs: nasal polyps in an adult with new unilateral nasal obstruction or epistaxis warrant imaging before any treatment — unilateral lesions can be inverted papilloma or sinonasal malignancy masquerading as a polyp Hopkins 2019. Empty nose syndrome is the iatrogenic consequence of aggressive inferior turbinate resection: paradoxical sensation of obstruction with a wide-open cavity, refractory to most interventions Houser 2007. Surgeons doing turbinate work should preserve mucosa and avoid total turbinectomy. Topical decongestant use beyond 3–5 days causes rhinitis medicamentosa — rebound congestion that locks patients into a cycle and is often mistaken for structural obstruction.

misconceptions

"Snoring means sleep apnoea, sleep apnoea means fix the nose." The reverse is closer to the truth. Isolated nasal surgery rarely cures obstructive sleep apnoea (the AHI rarely normalizes), though it improves CPAP compliance and reduces snoring intensity Georgalas 2011. The dominant OSA collapse sites are retropalatal and retroglossal — addressing the nose helps but is rarely sufficient alone.

"I have a deviated septum" as catch-all explanation for stuffiness. 89% of adults have radiographic septal deviation; only a minority are symptomatic Mladina et al. 2008. Most stuffiness is rhinitis-driven turbinate swelling, not the septum. The discriminating test: does it switch sides? Cyclical alternating obstruction is rhinitis-driven; constant unilateral obstruction is more often structural.

"Polyps are just allergies." CRSwNP is a distinct type-2 inflammatory disease; classical IgE-mediated allergic rhinitis is a contributor in some patients but not the cause. The marker is smell loss out of proportion to obstruction, plus the polyps themselves on endoscopy Stevens et al. 2016.

"Septoplasty is cosmetic." Septoplasty addresses the internal septum and does not change external appearance; rhinoplasty does. The two are sometimes combined (septorhinoplasty), but the functional procedure alone is covered by most insurance as medical, not cosmetic.

stakes

The typical reader is the chronically congested adult who has accepted mouth breathing as their baseline — wakes with a dry throat most mornings, snores at a level their partner has stopped commenting on, has lost smell so gradually they only notice when a friend points out spoiled milk in the fridge. Population data link nasal obstruction to fragmented sleep architecture, increased daytime sleepiness, and impaired concentration independent of formal OSA diagnosis Sundbom et al. 2021. Untreated CRSwNP carries a SNOT-22 burden similar to severe COPD or congestive heart failure — quality-of-life deficit, not life-threatening directly Hopkins 2019. The longevity tail runs through sleep: nasal obstruction is independently associated with prevalent OSA in population cohorts, and severe untreated OSA carries a cardiovascular mortality penalty Sundh et al. 2020.

payoff

Surgical and medical outcomes converge on a similar picture for responders: subjective congestion drops, snoring softens, dry-mouth mornings resolve, and (in CRSwNP) smell returns over weeks to months. SAMINOSE responders maintained their Glasgow Health Status gains through 24 months without regression van Egmond et al. 2019. Dupilumab responders in SINUS-52 recovered smell on UPSIT testing within 4 weeks and held it across 52 weeks of treatment Bachert et al. 2019. The onset latency varies: intranasal steroids take 2–6 weeks to plateau; septoplasty payoff appears once postoperative oedema resolves (4–6 weeks) and stabilizes by 3 months; biologics show measurable polyp shrinkage by week 4. Failure modes (next subsection) are also real — these are response rates, not guarantees.

failure-modes

Persistent symptoms after septoplasty in 15–25% of cohorts; explanations include unrecognized contralateral turbinate hypertrophy, internal nasal valve collapse missed on preoperative exam, and surgeon technique van Egmond et al. 2019. Polyp recurrence after FESS approaches 40–60% at 5 years in severe phenotype (eosinophilic CRSwNP with asthma) — the modern model treats CRSwNP as a chronic inflammatory disease with surgical episodes, not a curable condition Rimmer et al. 2014. Empty nose syndrome from over-aggressive turbinate resection: a serious iatrogenic outcome with no reliably curative treatment, hence the field-wide shift to mucosa-preserving techniques Houser 2007. Rhinitis medicamentosa from chronic decongestant use mimics structural obstruction; failure to recognize it leads to inappropriate surgery on a chemically dependent mucosa.

practicalities

Insurance coverage in the US is typically aligned with documented symptom burden plus failed medical management — NOSE ≥30 plus 4–8 weeks of intranasal steroid trial is the usual threshold for septoplasty authorization. Septoplasty is outpatient, 60–90 minutes under general anaesthesia, recovery 1–2 weeks; out-of-pocket cost varies from near-zero (with insurance) to $5,000–10,000 (cash). FESS for polyps runs longer and recovers over 2–3 weeks. Biologics are administered as subcutaneous injections every 2–4 weeks indefinitely; access requires specialist prescription and prior authorization through severity criteria. Intranasal corticosteroids (mometasone, fluticasone) are over-the-counter in most jurisdictions at <$100/year; high-volume saline irrigation kit costs <$50/year.

alternatives

External nasal dilators (adhesive strips, internal silicone cones) widen the nasal valve mechanically and reduce snoring in some users; their effect on objective sleep metrics is small and inconsistent. Useful as a diagnostic — a strong response suggests internal nasal valve collapse, not septal pathology. Mouth-taping at night forces nasal breathing but only helps if the nose is actually patent; it's incompatible with significant structural obstruction. CPAP bypasses the upper airway entirely; treats OSA but doesn't fix the underlying nasal lesion. Allergy management (allergen avoidance, antihistamines, allergen immunotherapy) addresses rhinitis-driven turbinate swelling but not fixed structural deviation or polyps. Mostly complementary rather than substitutive.

3. The credibility range

The optimist case

Structural nasal obstruction is one of the most reversible quality-of-life burdens in otolaryngology. Septoplasty's evidence base is now anchored by a pragmatic RCT showing durable subjective and quality-of-life benefit at 24 months — rare in surgical literature, which is dominated by case series van Egmond et al. 2019. For CRSwNP, the type-2 biologics are a generational shift: a disease previously managed with cycles of FESS and oral steroids now has targeted therapy reducing both polyp burden and rescue surgery Bachert et al. 2019. Restoration of smell — perhaps the most quality-of-life-defining sense people don't know they're missing until they get it back — is a documented benefit. The mechanism is rate-limiting (radius⁴), so even modest anatomical corrections produce disproportionate physiological relief. For an undertreated subset of the population, the right ENT workup is genuinely life-changing.

The skeptic case

Structural deviation is anatomically near-universal yet only sometimes symptomatic, which means clinical decision-making rests heavily on subjective scales (NOSE, SNOT-22) with no objective gold standard — rhinomanometry and acoustic rhinometry correlate poorly with patient-reported obstruction. The placebo effect of any nasal procedure is large; the SAMINOSE control arm itself improved from baseline. Septoplasty rates vary by an order of magnitude between countries and between surgeons within countries — a strong indicator of indication drift. Polyp recurrence after FESS is the rule, so surgery is often a temporary fix rather than a cure Rimmer et al. 2014. Biologics are extraordinarily expensive ($30–40k/year) for a non-fatal condition, and their long-term safety beyond 2–4 years is unknown. Turbinate surgery has a history of overaggressive practice that produced a generation of empty-nose patients with no good rescue Houser 2007. Most "nasal obstruction" is rhinitis-driven and resolves with medical management; reaching for structural correction first is over-treatment for many.

The author's call

Both cases hold; the resolution is in the workup, not in either-or framing. The honest position: for the chronically obstructed adult, a real ENT evaluation with endoscopy and a guided medical trial before surgical discussion is the high-value step the catalogue should push. When indicated and executed by a high-volume surgeon, septoplasty and FESS have durable benefit; mucosa-sparing turbinate reduction is safe. Biologics are transformative for refractory CRSwNP but rationed by cost. The entry is high-evidence on the medical-first ladder and the major surgical procedures; controversy is moderate, concentrated around indication thresholds and turbinate technique rather than fundamentals.

4. Stakeholder + incentive map

Otolaryngologists / rhinologists. Procedural specialty; income skews surgical. Honest practitioners self-regulate against over-operating, but international septoplasty rate variability suggests upstream financial incentive pressure is real. Society-level (American Rhinologic Society, EUFOREA) consensus has steadily tightened indication criteria.
Allergists / immunologists. Compete with surgeons for chronic-rhinitis and CRSwNP patients; pushed biologic therapy into the early-2020s mainstream. Cross-referral with rhinologists is the modern standard of care for severe CRSwNP.
Pharmaceutical industry. Heavy promotion of biologics (Sanofi/Regeneron — dupilumab; Genentech/Novartis — omalizumab; GSK — mepolizumab) for CRSwNP since FDA approvals. Patient advocacy groups partly industry-funded. List prices reflect oncology-tier pricing on a benign-disease indication.
Insurance payers. Counter-incentive to limit septoplasty and biologic authorization through prior-auth gates and severity thresholds; this both protects patients from over-treatment and frustrates appropriately indicated cases.
"Mouth-breathing" wellness community. Books (Breath, Nestor 2020), social-media nasal-breathing advocates, and dental-airway practitioners overstate what nasal-breathing alone can fix, sometimes routing patients away from indicated medical evaluation toward myofunctional therapy or mouth-tape products. Real signal underneath: chronic mouth breathing is genuinely consequential; the answer is sometimes structural correction, not just behavioral retraining.

5. Population variability

Sex. Septal deviation more common in adult men (higher nasal-trauma exposure). CRSwNP prevalence skews male (~60:40) and middle-aged. Turbinate hypertrophy and allergic rhinitis affect both sexes.
Age. CRSwNP peaks at 40–60 years; rare under 18 (paediatric polyps warrant cystic fibrosis workup). Septal deviation prevalence rises through adolescence and stabilizes in adulthood. Inferior turbinate hypertrophy from chronic rhinitis is age-agnostic.
Asthma / AERD. Patients with comorbid asthma have severe phenotype CRSwNP with high recurrence; AERD (Samter's triad — asthma + polyps + aspirin sensitivity) is the worst-prognosis subgroup and a primary indication for biologic therapy.
Allergic background. Allergic rhinitis amplifies turbinate hypertrophy and complicates the structural picture; treating allergies is upstream of judging the structural component.
Ethnic / anatomical variation. Nasal valve angle, columellar length, and turbinate size vary by ancestry; surgical technique adapts but the underlying physiology is conserved.
Children. Adenoid hypertrophy (not covered here — paediatric and a separate entry) is the dominant cause of paediatric nasal obstruction; chronic mouth breathing in childhood has documented effects on craniofacial development.

6. Knowledge gaps

Long-term (10-year+) outcomes of type-2 biologics for CRSwNP are unknown; safety and durability beyond the trial windows are still accruing. Head-to-head trials between biologic agents are absent; treatment selection is empirical. The objective–subjective discordance in nasal obstruction (rhinomanometry vs patient-reported) is unresolved and limits surgical patient selection. Internal nasal valve dysfunction — increasingly recognized as a missed cause of post-septoplasty failure — lacks standardized diagnostic criteria. The role of the nasal microbiome in CRSwNP pathogenesis is an active research area with no actionable clinical implication yet. The optimal threshold for biologic initiation versus repeat surgery in recurrent CRSwNP is genuinely contested. Empty nose syndrome's pathophysiology and treatment remain poorly understood despite the iatrogenic significance.

Scope held to the brief. The description named septal deviation, turbinate hypertrophy, nasal polyps, plus the consequences (breathing, sleep, smell, snoring) and the medical/surgical management split. The entry covers all of it. Sleep got the highest score (4) because the SAMINOSE responder profile and CRSwNP biologic trials show the most striking objective gains there; smell is part of health_short_term rather than its own dimension since the catalogue scoring rubric doesn't break out olfaction.

Excluded by design:

Paediatric structural obstruction (adenoid hypertrophy, paediatric polyps requiring cystic fibrosis workup) — different population, different evaluation pathway, warrants its own entry.
Sinonasal malignancy and inverted papilloma differential — flagged in contraindications as a referral trigger (unilateral lesion in an adult) but not detailed further; would mis-tune the felt-experience voice of the entry.
Empty nose syndrome treatment — mentioned in contraindications and failure-modes but not given full treatment; it's an iatrogenic outcome with no reliably curative therapy and arguably warrants a standalone entry.
Obstructive sleep apnoea workup and CPAP — strong adjacency but separate substance; flagged in out-of-scope.

Separate-entry candidates surfaced during writing:

chronic-rhinitis — the upstream driver of much turbinate hypertrophy; allergic and non-allergic variants.
obstructive-sleep-apnoea — downstream consequence; strong cross-link target.
upper-airway-resistance-syndrome (UARS) — the sub-apnoeic cousin, increasingly recognised.
rhinitis-medicamentosa — decongestant-rebound; could be its own small entry given how often it's mistaken for structural disease.
empty-nose-syndrome — iatrogenic, severe, no good treatment; field embarrassment worth its own page.

Rating difficulties. health_short_term straddles two phenotypes — the mildly congested adult who gains modestly from treatment, and the severe CRSwNP patient whose SNOT-22 burden matches severe COPD. Settled on 3 (meaningful, named effect) as the holistic call; arguably 4 for the severe phenotype alone. longevity is intentionally conservative at 1 — the longevity benefit runs entirely through OSA mitigation, which is a separate substance. controversy at 2 reflects mostly aligned consensus; the live disputes (turbinate technique, biologic vs revision surgery sequencing) are technical rather than foundational.

Voice call. Resisted the wellness-influencer framing of "nasal breathing as the master variable" that circulates in mouth-tape adjacent circles. The entry's frame is medical-decision-tree, not behavioral-retraining. The alternatives section explicitly positions mouth-taping as downstream of a patent nose, not a replacement for evaluation.

Future links to wire in when they exist: obstructive-sleep-apnoea, upper-airway-resistance-syndrome, chronic-rhinitis, mouth-tape, cpap, allergen-immunotherapy.